- BSP announced a €700 million investment plan for 2026–2030 at the DCAT Announcement Forum.
- The expansion will enhance manufacturing capabilities for oncology and advanced therapies at its Latina, Italy site.
BSP announced a €700 million investment plan for the 2026–2030 period during the DCAT Announcement Forum on March 23. The plan was presented by Anna Maria Braca, General Counsel and VP Strategic Business Development.
The investment will be focused entirely on the company’s site in Latina, Italy. According to the company, the expansion is intended to strengthen its integrated model and increase manufacturing capacity to meet demand in oncology and advanced therapies.
The company stated that the initiative will support its capabilities in bioconjugates and next-generation biologics manufacturing. The Latina site is positioned as an integrated hub for these activities within BSP’s CDMO and contract manufacturing operations.
BSP indicated that the expansion aligns with growing demand for specialized manufacturing services in oncology and advanced therapy segments.
